GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
27 avr. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on...
GBT Announces New Employment Inducement Grants
07 avr. 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2022, the compensation committee of GBT’s board...
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
24 mars 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the...
GBT Announces New Employment Inducement Grants
10 mars 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2022, the compensation committee of GBT’s board...
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
03 mars 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced it is...
GBT Announces Participation in Upcoming Investor Conferences
28 févr. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following...
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
23 févr. 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted...
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
16 févr. 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial...
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
16 févr. 2022 06h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the European Commission (EC) has granted Marketing Authorization...
GBT Announces New Employment Inducement Grants
03 févr. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2022, the compensation committee of GBT’s board...